Cassava Sciences Inc. (NASDAQ: SAVA) has launched a new clinical website called www.Rethink-ALZ.com meant to offer access, information, and visibility about the company’s third phase efficacy and safety results of oral simufilam in the treatment of Alzheimer’s disease patients. Simufilam is a novel oral drug candidate for the potential mild to moderate AD treatment.
The website will offer information to Alzheimer’s disease patients
The company’s Chief Clinical Development Officer James Kupiec said, “I think clinical sites around the country are quite excited by the potential of oral simufilam to impact Alzheimer’s disease. Rethink-ALZ.com is dedicated to enhance patient experience and enrollment for both of our ongoing Phase 3 studies of oral simufilam in Alzheimer’s disease.”
Individuals with Alzheimer’s disease can use Rethink-ALZ.com to complete a patient-friendly, caregiver-friendly pre-qualification questionnaire to discover if research participation is ideal for them. Interestingly if a person expresses interest, they are offered the choice of selecting the clinical trial location closest to them. This creates a connection with the website, and the user can then contact the website or request to be contacted for pre-screening.
Study to be conducted across 25 clinical sites
The Phase 3 effectiveness studies of simufilam in Alzheimer’s disease are already underway at over 25 clinical sites around the country.
Over the course of 52 weeks, the RETHINK-ALZ trial will assess the efficacy and safety of oral simufilam 100 mg in improving cognition and delaying cognitive and memory decline. Secondary goals include determining the impact of simufilam on neuropsychiatric symptoms and the costs of care. Approximately 750 patients with mild-to-moderate Alzheimer’s disease will be enrolled in this randomized, double-blind, placebo-controlled research in the United States and Canada, with intentions to expand to other countries in the future.
REFOCUS-ALZ, the second Phase 3 research, will assess the efficacy and safety of oral simufilam 100 mg and 50 mg over a 76-week period. The double-blind, randomized, placebo-controlled trial will enroll about 1,000 patients with mild-to-moderate Alzheimer’s disease in the United States and Canada, with intentions to expand to other countries in the future.
